EVOTEC SE INH O.N.
Commented by André Will-Laudien on July 31st, 2025 | 07:15 CEST
AI and biotech – A dream team for returns! Evotec and Novo Nordisk in the spotlight, and NetraMark steps on the gas!
The biotech sector is currently undergoing profound change: big data and artificial intelligence are revolutionizing the way drugs are researched and developed. AI-supported systems help identify molecular target structures more quickly and select active ingredients more precisely. Both start-ups and established companies are increasingly using data-based platforms to shorten development times and make clinical trials more successful. Investors are increasingly directing their capital toward companies that combine biotechnology with modern data analysis. The stock market is ruled by daily madness with figures that are not within the expected range. However, innovative growth markets will remain volatile and attractive at the same time, so bet on the winners!
Read
Commented by André Will-Laudien on July 25th, 2025 | 07:05 CEST
Biotech turns to gold: Who is swallowing whom - or what? Evotec, BioNxt, Valneva, and Formycon are on the list!
The biotech sector is closely monitoring central bank interest rates. At present, however, inflation still seems a little too high to expect significant cuts. Accordingly, the European Central Bank left its key interest rates unchanged yesterday. Investors are now looking to Wall Street for signals on where rates might head in the second half of the year. However, due to the sharp price increases on the Nasdaq and existing undervaluations, takeover rumors are starting to circulate - and could materialize at any time. BioNxt, Evotec, and Valneva are on our watchlist. Where do the opportunities lie for investors?
Read
Commented by Fabian Lorenz on July 23rd, 2025 | 07:10 CEST
TAKEOVER SPECULATION! Barrick Mining, Evotec, Desert Gold
Just like the high prices, takeover speculation in the gold sector is also continuing. Desert Gold is repeatedly mentioned as a candidate. With its exciting acquisition in West Africa, the explorer has diversified and made itself even more attractive to a large corporation. Perhaps Barrick? The heavyweight is currently focusing on its ore mines and selling smaller projects. It could then expand again in the gold sector, and Desert certainly fits in regionally. In the biotech sector, Evotec has long been rumored as a takeover candidate. Following the latest revenue warning, this is likely the only hope for investors to achieve short-term returns. Or was the price slide exaggerated?
Read
Commented by Armin Schulz on July 17th, 2025 | 07:05 CEST
Bayer, NetraMark, Evotec: How AI Research is accelerating returns and could optimize your portfolio
In 2025, the healthcare industry is undergoing a radical transformation driven by AI and advanced technologies. While pharmaceutical giants struggle with cost pressures and regulatory hurdles, algorithms are revolutionizing drug development by decoding clinical data in record time and enabling personalized therapies. In this period of disruption, innovative strength will determine victory or decline. Three companies are at the forefront of this shift: Bayer, with its broad portfolio; NetraMark, leveraging AI-powered data analysis; and Evotec, with its disruptive research collaborations. Find out what is currently driving these stocks.
Read
Commented by Fabian Lorenz on July 11th, 2025 | 07:20 CEST
Biotech takeover merry-go-round picks up speed! BioNTech, Evotec, Merck, and BioNxt Solutions!
The takeover merry-go-round is spinning faster again in the biotech sector. The latest example is Merck's acquisition of Verona Pharma. The US group is paying USD 10 billion for the deal. BioNxt Solutions would be significantly cheaper to acquire at present. The Company aims to make it easier to take medication with melt films, skin patches, and tablets. In addition, it has now announced an exciting platform. The goal is to develop smarter chemotherapy, which, in turn, could create a billion-dollar market. And what are BioNTech and Evotec doing? Things have quieted down a bit at the German biotech leader following its billion-dollar deal with Bristol-Myers Squibb. However, analysts recommend buying the stock. Evotec, on the other hand, is languishing at around EUR 7. Can the quarterly figures provide new impetus for the struggling stock?
Read
Commented by Fabian Lorenz on July 3rd, 2025 | 07:05 CEST
Plug Power +71%! CAUTION with Evotec! Buy Walmart partner MiMedia shares?
A 71% share price increase in one month. Is this the resurrection of Plug Power shares? The performance is certainly impressive: operational news, insider buying, and a short squeeze are creating a dynamic mix. However, the fundamental problems remain. Those looking for an exciting stock for the second half of the year should take a closer look at MiMedia. The report on the first six months of this cloud hidden gem is expected to be positive and could drive the stock to a new high after its sideways movement. And what is Evotec doing? After last week's positive news, hopes for an upward trend were high. However, analysts are warning of a possible profit warning at the biotech company.
Read
Commented by Armin Schulz on July 2nd, 2025 | 07:10 CEST
AI, personalized therapies, blockbusters: Evotec, NetraMark Holdings, Novo Nordisk – Your ticket to the pharmaceutical boom
As billion-dollar profits beckon and technological quantum leaps revolutionize the healthcare industry, investor excitement is surging in 2025. Investors are flocking back, attracted by unprecedented momentum. Artificial intelligence is discovering new drug candidates in record time, personalized medicine is unlocking entirely new markets, and solutions for widespread chronic diseases are driving valuations to dizzying heights. Those who understand the rules of this rapid change and identify the right partners are positioning themselves for exceptional returns. We therefore take a closer look at three compelling companies in this space: Evotec, NetraMark Holdings, and Novo Nordisk.
Read
Commented by André Will-Laudien on June 30th, 2025 | 07:35 CEST
Takeover fever! Biotech and artificial intelligence boost Evotec, NetraMark Holdings, Novo Nordisk, and Bayer
The biotech sector is currently undergoing an exciting transformation, as big data and artificial intelligence are rapidly changing the way new drugs are discovered, developed, and tested. The use of learning algorithms allows molecular target structures to be identified more quickly and potential active ingredients to be evaluated more efficiently. Start-ups and established players alike are increasingly turning to data-driven platforms to reduce research costs and increase the success rate of clinical trials. As a result, capital is increasingly flowing into companies that use modern data analysis to drive biotechnology. Approaches that enable personalized medicine - treatments precisely tailored to an individual's specific condition - are in particularly high demand. For investors, this represents a promising growth sector with enormous disruptive potential. But who are the most interesting players?
Read
Commented by André Will-Laudien on June 26th, 2025 | 07:00 CEST
New biotech boom ignites: Are Evotec, BioNxt, Bayer, Novo Nordisk, and Formycon poised for the next price surge?
The biotechnology industry is currently experiencing a remarkable renaissance. Innovations in personalized medicine, advances in mRNA technologies, and new therapeutic approaches to cancer and autoimmune diseases are fueling investor interest worldwide. In this dynamic environment, established players such as Evotec and Bayer, as well as specialized up-and-comers like BioNxt and Formycon, are moving into the spotlight of strategic investments. While Evotec scores with its strong partner network, Bayer is working on a realignment with a focus on promising research. BioNxt impresses with a lean business model and promising pipeline products in the field of drug delivery. Formycon, on the other hand, is benefiting from the biosimilar boom and is currently undergoing a turnaround. The industry is highly innovation-driven, and those who bet on the right players could reap above-average rewards.
Read
Commented by Fabian Lorenz on June 25th, 2025 | 07:30 CEST
BioNTech swallows CureVac! Evotec and Vidac Pharma next? Price driver takeover and Buy recommendation
Is Vidac Pharma about to see another price explosion? Last fall, the share rose by around 200%. Yesterday, there was a "Buy" recommendation. Analysts see potential for growth in this biotech gem. The latest news on the drug candidate VDA 1102 for brain tumors is promising. Could a takeover be on the cards? CureVac's share price has nearly doubled since the beginning of April. BioNTech plans to acquire its mRNA competitor and thus end patent disputes. Evotec is a permanent fixture on the takeover merry-go-round. However, this currently seems to be the only hope for rising share prices. The management's new strategy has not created the hoped-for wave of optimism. Is it still worth buying now?
Read